Latest revenue
$4.7M
as of 2025-09-30
Latest net income
$-46.4M
as of 2025-09-30
Net margin
-991.4%
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AVXL is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $238.6M
- Enterprise value
- $107.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.88×
- Dividend yield
- 0.0%
- 52-wk high
- $13.99
- 52-wk low
- $2.56
- Beta
- —
- Shares out
- 92.7M
5-year trend
What this company does
ITEM 1. BUSINESS Overview and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials. The Company’s focus is on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Our research and development pipeline includes ANAVEX®2-73…
AI summary unavailable — showing raw filing excerpt
Generated from AVXL's filing dated 2025-11-25
Key risks
ITEM 1A. RISK FACTORS Risk Factor Summary The following is a summary of the risks and uncertainties that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk factors contained in this report in their entirety for additional information regarding these risks and uncertainties. ·Our history of losses and no revenue raises a risk regarding our ability to continue as a going concern in the future; ·We have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made; ·Our research and development plans will require substantial additional future funding; ·We may be…
AI summary unavailable — showing raw filing excerpt
Generated from AVXL's filing dated 2025-11-25
Profitability
Operating margin
-1098.9%
52.1%Net margin
-991.4%
68.8%Return on equity
-48.9%
36.7%Return on assets
-44.7%
40.8%Leverage
Debt / equity
0.09×
25.9%Long-term debt / equity
0.00×
Debt / assets
8.6%
23.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-5.7M | +53.1% | — |
Q3 2025 2025-09-30 | — | — | $-9.8M | +15.4% | — |
Q2 2025 2025-06-30 | — | — | $-13.2M | -8.4% | — |
Q1 2025 2025-03-31 | — | — | $-11.2M | -6.2% | — |
Q4 2024 2024-12-31 | — | — | $-12.1M | -40.5% | — |
Q3 2024 2024-09-30 | — | — | $-11.6M | — | — |
Q2 2024 2024-06-30 | — | — | $-12.2M | -8.3% | — |
Q1 2024 2024-03-31 | — | — | $-10.5M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on AVXL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVXL
Institutional value
$57.9M
Total shares held
19.0M
Distinct holders
117
-66 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.6M | $23.4M | +83.5K (+1.1%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $11.9M | — | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 783.1K | $2.4M | — | New |
| 4 | JANE STREET GROUP, LLC | 725.0K | $2.2M | -44.0K (-5.7%) | Trimmed |
| 5 | VANGUARD FIDUCIARY TRUST CO | 647.2K | $2.0M | — | New |
| 6 | UBS Group AG | 570.0K | $1.7M | +110.6K (+24.1%) | Added |
| 7 | FEDERATED HERMES, INC. | 532.3K | $1.6M | +164.4K (+44.7%) | Added |
| 8 | Private Advisor Group, LLC | 499.7K | $1.5M | +79.9K (+19.0%) | Added |
| 9 | LPL Financial LLC | 418.6K | $1.3M | -110.1K (-20.8%) | Trimmed |
| 10 | Bank of New York Mellon Corp | 247.8K | $760.9K | +3.8K (+1.6%) | Added |
| 11 | STIFEL FINANCIAL CORP | 236.8K | $727.0K | +135.8K (+134.4%) | Added |
| 12 | Apella Capital, LLC | 153.0K | $556.9K | +15.0K (+10.9%) | Added |
| 13 | Nuveen, LLC | 169.2K | $519.3K | +779 (+0.5%) | Added |
| 14 | ENVESTNET ASSET MANAGEMENT INC | 129.2K | $396.6K | +41.5K (+47.3%) | Added |
| 15 | 180 WEALTH ADVISORS, LLC | 119.5K | $366.8K | +2.1K (+1.8%) | Added |
| 16 | SHEETS SMITH WEALTH MANAGEMENT | 117.8K | $361.7K | +109 (+0.1%) | Added |
| 17 | Creative Planning | 108.3K | $332.6K | +35.6K (+48.9%) | Added |
| 18 | HSBC HOLDINGS PLC | 107.9K | $330.0K | +50.3K (+87.4%) | Added |
| 19 | RHUMBLINE ADVISERS | 106.1K | $325.8K | -1.3K (-1.2%) | Trimmed |
| 20 | WELLS FARGO & COMPANY/MN | 79.4K | $243.9K | -54.4K (-40.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AVXL's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.